Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Mechanism of Action
Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1.
Dosage Overview
Dose Range
300 mcg – 4.5 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
26–68 weeks
Reconstitution
Typical Dosage (Research)
Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.
Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.
Considerations for Men & Women
Women: Amylin analog; same pregnancy precautions as GLP-1 class. Being studied in combination with semaglutide (CagriSema). May affect oral contraceptive absorption. Weight loss benefits may improve PCOS symptoms.
Men: Weight loss may improve obesity-related hypogonadism. No sex-specific dose adjustments in clinical trials.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 2,500 mcg/ml
Volume to inject: 0.12 ml
Syringe units (U-100): 12.0 units
Pre-filled with Cagrilintide defaults. Adjust values as needed.
Side Effects & Risks
Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.
Investigational compound - full safety profile being established. Expected to carry similar warnings to approved amylin analog pramlintide.
Where to Buy Cagrilintide
All Vendor Details →US-based vendor with third-party HPLC testing and published COAs. One of the few reputable sources we've verified for research-grade peptides.
Some links on this page are affiliate links — we may earn a commission at no extra cost to you. Learn more.
Finnrick grades are based on independent HPLC lab testing. Learn more · Finnrick is a commercial service — ratings are third-party, not independent.
Who Uses Cagrilintide
Currently clinical trial participants only. Expected to target those seeking enhanced weight loss beyond GLP-1 monotherapy.
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.